C
Cindy Delbrook
Researcher at National Institutes of Health
Publications - 31
Citations - 4737
Cindy Delbrook is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Leukemia & Cytokine release syndrome. The author has an hindex of 16, co-authored 30 publications receiving 3482 citations.
Papers
More filters
Journal ArticleDOI
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
TL;DR: CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Journal ArticleDOI
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J. Fry,Nirali N. Shah,Rimas J. Orentas,Maryalice Stetler-Stevenson,Constance M. Yuan,Sneha Ramakrishna,Pamela L. Wolters,Staci Martin,Cindy Delbrook,Bonnie Yates,Haneen Shalabi,Thomas J. Fountaine,Jack F. Shern,Robbie G. Majzner,David F. Stroncek,Marianna Sabatino,Yang Feng,Dimiter S. Dimitrov,Ling Zhang,Sang M. Nguyen,Haiying Qin,Boro Dropulic,Daniel W. Lee,Crystal L. Mackall +23 more
TL;DR: These results are the first to establish the clinical activity of a CD22-CAR in B-all, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses.
Journal ArticleDOI
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Melinda S. Merchant,Matthew Wright,Kristin Baird,Leonard H. Wexler,Carlos Rodriguez-Galindo,Donna Bernstein,Cindy Delbrook,Maya Lodish,Rachel Bishop,Jedd D. Wolchok,Howard Streicher,Crystal L. Mackall +11 more
TL;DR: Although no objective tumor regressions were observed with ipilimumab as a single agent, subjects with immune-related toxicities had an increased overall survival compared with those who showed no evidence of breaking tolerance.
Journal ArticleDOI
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah,Steven L. Highfill,Haneen Shalabi,Bonnie Yates,Jianjian Jin,Pamela L. Wolters,Amanda K. Ombrello,Seth M. Steinberg,Staci Martin,Cindy Delbrook,Leah Hoffman,Lauren Little,Anusha Ponduri,Haiying Qin,Haris Qureshi,Alina Dulau-Florea,Dalia Salem,Hao-Wei Wang,Constance M. Yuan,Maryalice Stetler-Stevenson,Sandhya R. Panch,Minh Tran,Crystal L. Mackall,Crystal L. Mackall,David F. Stroncek,Terry J. Fry,Terry J. Fry +26 more
TL;DR: The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy, and novel information on the impact of manufacturing changes on clinical outcomes is provided.
Journal ArticleDOI
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Nirali N. Shah,Daniel W. Lee,Bonnie Yates,Constance M. Yuan,Haneen Shalabi,Staci Martin,Pamela L. Wolters,Seth M. Steinberg,Eva H. Baker,Cindy Delbrook,Maryalice Stetler-Stevenson,Terry J. Fry,David F. Stroncek,Crystal L. Mackall +13 more
TL;DR: PURPOSECD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL) but relapse rates are high as discussed by the authors.